Identification
- Summary
Lacosamide is an antiepileptic drug used to treat partial onset seizures in adults.
- Brand Names
- Vimpat
- Generic Name
- Lacosamide
- DrugBank Accession Number
- DB06218
- Background
Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Lacosamide (DB06218)
- Weight
- Average: 250.2936
Monoisotopic: 250.131742452 - Chemical Formula
- C13H18N2O3
- Synonyms
- Erlosamide
- Harkoseride
- Lacosamida
- Lacosamide
- External IDs
- ADD 243037
- ADD-243037
- SPM 927
- SPM-927
Pharmacology
- Indication
Lacosamide is indicated for the treatment of partial-onset seizures in patients aged one month and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged four years and older.3
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Lacosamide therapy is correlated with a decrease in seizure frequency. It should be noted that in group analyses, dosages above 400 mg/day do not appear to result in additional benefit.
- Mechanism of action
It is proposed that lacosamide's inhibition of sodium channels is responsible for analgesia. Lacosamide may be selective for inhibiting depolarized neurons rather than neurons with normal resting potentials. Pain and nociceptor hyperexcitability are associated with neural membrane depolarization. Lacosamide binds to collapsin response mediator protein-2 (CRMP-2), a phosphoprotein which is expressed primarily in the nervous system and is involved in neuronal differentiation and control of axonal outgrowth. The role CRMP-2 of binding in seizure control is hasn't been elucidated.
Target Actions Organism USodium channel protein type 9 subunit alpha Not Available Humans USodium channel protein type 3 subunit alpha Not Available Humans USodium channel protein type 10 subunit alpha Not Available Humans - Absorption
Lacosamide has a negligible first pass effect with bioavailability of about 100%. The maximum Lacosamide plasma concentrations occur about 1-4 hours after oral administration, and the pharmacokinetics of Lacosamide are dose proportional. Food does not affect absorption.
- Volume of distribution
approximately 0.6 L/kg; thus close to the volume of total body water.
- Protein binding
<15%
- Metabolism
Lacosamide is a CYP2C19 substrate. The relative contribution of other CYP isoforms or non-CYP enzymes in the metabolism of lacosamide is not known. Primary compounds excreted were unchanged lacosamide (approximately 40% of the dose), its O-desmethyl metabolite (approximately 30%), and a structurally unknown polar fraction (~20%). The plasma exposure of the major human metabolite, O-desmethyl-lacosamide, is approximately 10% of that of lacosamide. This metabolite has no known pharmacological activity.
Hover over products below to view reaction partners
- Route of elimination
Lacosamide is eliminated primarily from the systemic circulation by biotransformation and renal excretion.
- Half-life
13 Hours
- Clearance
95% recovered in the urine 0.5% in the feces
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Cytochrome P450 2C19 CYP2C19*2A Not Available 681G>A Effect Inferred Reduced O-desmethyl metabolite concentrations in plasma. Details Cytochrome P450 2C19 CYP2C19*2B Not Available 681G>A Effect Inferred Reduced O-desmethyl metabolite concentrations in plasma. Details Cytochrome P450 2C19 CYP2C19*3 Not Available 636G>A Effect Inferred Reduced O-desmethyl metabolite concentrations in plasma. Details Cytochrome P450 2C19 CYP2C19*4 Not Available 1A>G Effect Inferred Reduced O-desmethyl metabolite concentrations in plasma. Details Cytochrome P450 2C19 CYP2C19*5 Not Available 1297C>T Effect Inferred Reduced O-desmethyl metabolite concentrations in plasma. Details Cytochrome P450 2C19 CYP2C19*6 Not Available 395G>A Effect Inferred Reduced O-desmethyl metabolite concentrations in plasma. Details Cytochrome P450 2C19 CYP2C19*7 Not Available 19294T>A Effect Inferred Reduced O-desmethyl metabolite concentrations in plasma. Details Cytochrome P450 2C19 CYP2C19*22 Not Available 557G>C / 991A>G Effect Inferred Reduced O-desmethyl metabolite concentrations in plasma. Details Cytochrome P450 2C19 CYP2C19*24 Not Available 99C>T / 991A>G … show all Effect Inferred Reduced O-desmethyl metabolite concentrations in plasma. Details Cytochrome P450 2C19 CYP2C19*35 Not Available 12662A>G Effect Inferred Reduced O-desmethyl metabolite concentrations in plasma. Details
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Lacosamide is combined with 1,2-Benzodiazepine. Abametapir The serum concentration of Lacosamide can be increased when it is combined with Abametapir. Abatacept The metabolism of Lacosamide can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Lacosamide. Abrocitinib The metabolism of Abrocitinib can be decreased when combined with Lacosamide. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Lacosamide. Acebutolol Acebutolol may increase the bradycardic activities of Lacosamide. Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Lacosamide. Acetaminophen The metabolism of Lacosamide can be increased when combined with Acetaminophen. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Lacosamide. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Take with or without food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Images
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Alembic-lacosamide Tablet 100 mg Oral Alembic Pharmaceuticals Limited Not applicable Not applicable Canada 
Alembic-lacosamide Tablet 200 mg Oral Alembic Pharmaceuticals Limited Not applicable Not applicable Canada Alembic-lacosamide Tablet 50 mg Oral Alembic Pharmaceuticals Limited Not applicable Not applicable Canada Alembic-lacosamide Tablet 150 mg Oral Alembic Pharmaceuticals Limited Not applicable Not applicable Canada Lacosamide Tablet 50 mg Oral Jubilant Generics Limited Not applicable Not applicable Canada Lacosamide Tablet 200 mg Oral Sanis Health Inc 2021-09-27 Not applicable Canada Lacosamide Tablet 50 mg Oral Sanis Health Inc 2021-09-27 Not applicable Canada Lacosamide Tablet 150 mg Oral Jubilant Generics Limited Not applicable Not applicable Canada Lacosamide Solution 150 mg/15mL Oral Vistapharm, Inc. 2021-11-15 Not applicable US 
Lacosamide Tablet 150 mg Oral Sanis Health Inc 2021-09-27 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ach-lacosamide Tablet 150 mg Oral Accord Healthcare Inc 2021-04-27 Not applicable Canada Ach-lacosamide Tablet 100 mg Oral Accord Healthcare Inc 2021-04-27 Not applicable Canada Ach-lacosamide Tablet 200 mg Oral Accord Healthcare Inc 2021-04-27 Not applicable Canada Ach-lacosamide Tablet 50 mg Oral Accord Healthcare Inc 2021-04-27 Not applicable Canada Ag-lacosamide Tablet 50 mg Oral Angita Pharma Inc. 2021-12-24 Not applicable Canada Ag-lacosamide Tablet 150 mg Oral Angita Pharma Inc. 2021-12-24 Not applicable Canada Ag-lacosamide Tablet 100 mg Oral Angita Pharma Inc. 2021-12-24 Not applicable Canada Ag-lacosamide Tablet 200 mg Oral Angita Pharma Inc. 2022-04-29 Not applicable Canada Apo-lacosamide Tablet 100 mg Oral Apotex Corporation Not applicable Not applicable Canada Apo-lacosamide Tablet 200 mg Oral Apotex Corporation Not applicable Not applicable Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ELEPSİ 50 MG+100 MG TEDAVİYE BAŞLAMA PAKETİ, 42 ADET Lacosamide (50 mg) + Lacosamide (100 mg) Tablet, film coated Oral SANTA FARMA İLAÇ SAN. A.Ş. 2020-08-14 Not applicable Turkey 
ELEPSİ 50 MG+100 MG TEDAVİYE BAŞLAMA PAKETİ, 42 ADET Lacosamide (50 mg) + Lacosamide (100 mg) Tablet, film coated Oral SANTA FARMA İLAÇ SAN. A.Ş. 2020-08-14 Not applicable Turkey LAMIDE TEDAVIYE BAŞLAMA PAKETI, 56 ADET Lacosamide (50 mg) + Lacosamide (100 mg) + Lacosamide (150 mg) + Lacosamide (200 mg) Tablet, film coated Oral ALİ RAİF İLAÇ SAN. A.Ş. 2020-08-14 Not applicable Turkey LAMIDE TEDAVIYE BAŞLAMA PAKETI, 56 ADET Lacosamide (50 mg) + Lacosamide (100 mg) + Lacosamide (150 mg) + Lacosamide (200 mg) Tablet, film coated Oral ALİ RAİF İLAÇ SAN. A.Ş. 2020-08-14 Not applicable Turkey LAMIDE TEDAVIYE BAŞLAMA PAKETI, 56 ADET Lacosamide (50 mg) + Lacosamide (100 mg) + Lacosamide (150 mg) + Lacosamide (200 mg) Tablet, film coated Oral ALİ RAİF İLAÇ SAN. A.Ş. 2020-08-14 Not applicable Turkey LAMIDE TEDAVIYE BAŞLAMA PAKETI, 56 ADET Lacosamide (50 mg) + Lacosamide (100 mg) + Lacosamide (150 mg) + Lacosamide (200 mg) Tablet, film coated Oral ALİ RAİF İLAÇ SAN. A.Ş. 2020-08-14 Not applicable Turkey Vimpat Lacosamide (50 mg/1) + Lacosamide (100 mg/1) Kit; Tablet, film coated Oral UCB, Inc. 2009-05-26 2015-12-15 US Vimpat Lacosamide (50 mg/1) + Lacosamide (100 mg/1) Kit; Tablet, film coated Oral UCB, Inc. 2009-05-26 2015-12-15 US
Categories
- ATC Codes
- N03AX18 — Lacosamide
- Drug Categories
- Acetamides
- Acetates
- Acids, Acyclic
- Alkanes
- Amides
- Anti-epileptic Agent
- Anticonvulsants
- Bradycardia-Causing Agents
- Cardiovascular Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Cytochrome P-450 CYP2C19 Substrates
- Cytochrome P-450 CYP2C9 Substrates
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A4 Substrates (strength unknown)
- Cytochrome P-450 Substrates
- Decreased Central Nervous System Disorganized Electrical Activity
- Hydrocarbons, Acyclic
- Membrane Transport Modulators
- Miscellaneous Anticonvulsants
- Nervous System
- Sodium Channel Blockers
- Voltage-Gated Sodium Channel Blockers
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- N-acyl-alpha amino acids and derivatives
- Alternative Parents
- Alpha amino acid amides / Benzene and substituted derivatives / Acetamides / Secondary carboxylic acid amides / Dialkyl ethers / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Acetamide / Alpha-amino acid amide / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxamide group / Dialkyl ether / Ether / Hydrocarbon derivative / Monocyclic benzene moiety
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 563KS2PQY5
- CAS number
- 175481-36-4
- InChI Key
- VPPJLAIAVCUEMN-GFCCVEGCSA-N
- InChI
- InChI=1S/C13H18N2O3/c1-10(16)15-12(9-18-2)13(17)14-8-11-6-4-3-5-7-11/h3-7,12H,8-9H2,1-2H3,(H,14,17)(H,15,16)/t12-/m1/s1
- IUPAC Name
- (2R)-N-benzyl-2-acetamido-3-methoxypropanamide
- SMILES
- COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1
References
- Synthesis Reference
http://www.google.com/patents?id=IIanAAAAEBAJ&pg=PA2&source=gbsselectedpages&cad=3#v=onepage&q&f=false
- General References
- Sheets PL, Heers C, Stoehr T, Cummins TR: Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J Pharmacol Exp Ther. 2008 Jul;326(1):89-99. doi: 10.1124/jpet.107.133413. Epub 2008 Mar 31. [Article]
- Jones GL, Popli GS, Silvia MT: Lacosamide-induced valproic acid toxicity. Pediatr Neurol. 2013 Apr;48(4):308-10. doi: 10.1016/j.pediatrneurol.2012.12.039. [Article]
- FDA Approved Drug Products: VIMPAT (lacosamide) for oral and intravenous use [Link]
- External Links
- KEGG Drug
- D07299
- PubChem Compound
- 219078
- PubChem Substance
- 175427063
- ChemSpider
- 189902
- BindingDB
- 50300204
- 623400
- ChEBI
- 135939
- ChEMBL
- CHEMBL58323
- ZINC
- ZINC000000007673
- PharmGKB
- PA166160048
- Wikipedia
- Lacosamide
- FDA label
- Download (276 KB)
- MSDS
- Download (570 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Epilepsies 2 4 Completed Treatment Partial Epilepsy 4 4 Recruiting Prevention Opioid-induced Respiratory Depression 1 4 Terminated Treatment Seizures 1 4 Unknown Status Treatment Epilepsies 1 3 Active Not Recruiting Treatment Epilepsies 1 3 Completed Treatment Diabetic Neuropathies 2 3 Completed Treatment Epilepsies 12 3 Completed Treatment Epilepsies / Monotherapy 2 3 Completed Treatment Epilepsies / Partial-Onset Seizures 4
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intravenous 10 mg/ml Syrup Oral 1 g Tablet, coated Oral 200 mg Solution Parenteral Syrup Oral Tablet, film coated Oral Injection, solution Intravenous 10 mg/1mL Solution Oral 10 mg/1mL Solution Oral 100 mg/10mL Solution Oral 150 mg/15mL Solution Oral 200 mg/20mL Solution Oral 50 mg/5mL Tablet Oral 100 mg/1 Tablet Oral 150 mg/1 Tablet Oral 200 mg/1 Tablet Oral 50 mg/1 Tablet, film coated Oral 100 mg/1 Tablet, film coated Oral 150 mg/1 Tablet, film coated Oral 200 mg/1 Tablet, film coated Oral 100 MG Tablet, film coated Oral 150 MG Tablet, film coated Oral 50 MG Injection, solution Intravenous Tablet, film coated Oral Capsule, extended release Oral 100 mg/1 Capsule, extended release Oral 150 mg/1 Capsule, extended release Oral 200 mg/1 Injection Intravenous 10 mg/1mL Kit; tablet, film coated Oral Solution Intravenous 10 mg / mL Syrup Oral 10 MG/ML Syrup Oral 15 MG/ML Tablet Oral 100 mg Tablet Oral 150 mg Tablet Oral 200 mg Tablet Oral 50 mg Tablet, coated Oral Tablet, film coated Oral 50 mg/1 Solution Oral 1000 mg Tablet, coated Oral 100 mg Tablet, coated Oral 50 mg Syrup Oral 15 mg Syrup Oral 10 mg/1ml Tablet, film coated Oral 200 mg Tablet, coated Oral 150 mg Solution Intravenous 200 mg Injection, solution Intravenous 10 mg/ml - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5654301 No 1997-08-05 2014-08-05 US USRE38551 No 2004-07-06 2022-03-17 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 140-146˚C http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500064326.pdf boiling point (°C) 536.447 °C at 760 mmHg ACD/Labs water solubility Lacosamide is a white to light yellow powder. It is sparingly soluble in water and slightly soluble in acetonitrile and ethanol. FDA Label logP 0.728 ACD/Labs - Predicted Properties
Property Value Source Water Solubility 0.465 mg/mL ALOGPS logP 0.18 ALOGPS logP -0.022 Chemaxon logS -2.7 ALOGPS pKa (Strongest Acidic) 12.46 Chemaxon pKa (Strongest Basic) -2 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 67.43 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 67.57 m3·mol-1 Chemaxon Polarizability 26.68 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9771 Blood Brain Barrier + 0.7181 Caco-2 permeable - 0.6886 P-glycoprotein substrate Substrate 0.7158 P-glycoprotein inhibitor I Non-inhibitor 0.6904 P-glycoprotein inhibitor II Non-inhibitor 0.8878 Renal organic cation transporter Non-inhibitor 0.8757 CYP450 2C9 substrate Non-substrate 0.8732 CYP450 2D6 substrate Non-substrate 0.7634 CYP450 3A4 substrate Non-substrate 0.6572 CYP450 1A2 substrate Non-inhibitor 0.8084 CYP450 2C9 inhibitor Non-inhibitor 0.8704 CYP450 2D6 inhibitor Non-inhibitor 0.8775 CYP450 2C19 inhibitor Non-inhibitor 0.8201 CYP450 3A4 inhibitor Non-inhibitor 0.837 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9732 Ames test Non AMES toxic 0.7694 Carcinogenicity Non-carcinogens 0.8388 Biodegradation Not ready biodegradable 0.8499 Rat acute toxicity 2.1629 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9678 hERG inhibition (predictor II) Non-inhibitor 0.8489
Spectra
- Mass Spec (NIST)
- Download (18.4 KB)
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Voltage-gated sodium channel activity
- Specific Function
- Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
- Gene Name
- SCN9A
- Uniprot ID
- Q15858
- Uniprot Name
- Sodium channel protein type 9 subunit alpha
- Molecular Weight
- 226370.175 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Voltage-gated sodium channel activity
- Specific Function
- Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a...
- Gene Name
- SCN3A
- Uniprot ID
- Q9NY46
- Uniprot Name
- Sodium channel protein type 3 subunit alpha
- Molecular Weight
- 226291.905 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Voltage-gated sodium channel activity
- Specific Function
- Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
- Gene Name
- SCN10A
- Uniprot ID
- Q9Y5Y9
- Uniprot Name
- Sodium channel protein type 10 subunit alpha
- Molecular Weight
- 220623.605 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Contin M, Albani F, Riva R, Candela C, Mohamed S, Baruzzi A: Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit. 2013 Dec;35(6):849-52. doi: 10.1097/FTD.0b013e318290eacc. [Article]
- Bentue-Ferrer D, Tribut O, Verdier MC: [Therapeutic drug monitoring of lacosamide]. Therapie. 2012 Mar-Apr;67(2):151-5. doi: 10.2515/therapie/2012012. Epub 2012 Aug 2. [Article]
- Chung SS: New treatment option for partial-onset seizures: efficacy and safety of lacosamide. Ther Adv Neurol Disord. 2010 Mar;3(2):77-83. doi: 10.1177/1756285609355850. [Article]
- Drugs.com Lacosamide Monograph [Link]
- FDA Approved Drug Products: VIMPAT (lacosamide) for oral or intravenous use [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- FDA Approved Drug Products: VIMPAT (lacosamide) for oral or intravenous use [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- FDA Approved Drug Products: VIMPAT (lacosamide) for oral or intravenous use [Link]
Drug created at March 19, 2008 16:17 / Updated at May 31, 2023 00:21